Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism
- 1 January 2012
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 107 (01), 37-43
- https://doi.org/10.1160/th11-06-0423
Abstract
Long-term therapy with low-molecular-weight heparin (LMWH) is the treatment of choice for cancer patients with venous thromboembolism (VTE). However, the ideal doses of LMWH have not been thoroughly studied. We used the RIETE Registry data to assess the influence of the daily LMWH dosage on outcome during the first three months after VTE. We used propensity score-matching to compare patients who received <150 vs. those receiving ≥150 UI/kg/day LMWH. Up to July 2010, 3,222 cancer patients with VTE received long-term therapy with fixed doses of LMWH. Of these, 1,472 (46%) received <150 IU/kg/day (mean, 112 ± 28), and 1,750 received ≥150 IU/kg/day (mean, 184 ± 32). Results of the propensity score matching involved 1269 matched pairs. During follow-up, the incidence of pulmonary embolism (PE) recurrences was similar (1.2% vs. 1.9%), but patients receiving <150 IU/kg/day LMWH had a lower incidence of fatal PE than those treated with ≥150 IU/kg/day (0.2% vs. 1.0%; p=0.004). Multivariate analysis confirmed that patients receiving <150 IU/kg/day LMWH had a lower risk for fatal PE (odds ratio [OR]: 0.2; 95% confidence interval [CI]: 0.06–0.8) and for major bleeding (OR: 0.6; 95% CI: 0.3–1.0) than those treated with ≥150 IU/kg/day. In real life, one in every two cancer patients with VTE received lower doses of LMWH than those used in randomised trials, with large variations from patient to patient. Unexpectedly, patients treated with <150 IU/kg/day LMWH had fewer fatal PE cases and fewer major bleeding events than those receiving ≥150 IU/kg/day LMWH. This finding, however, should be validated in prospective clinical trials.Keywords
This publication has 21 references indexed in Scilit:
- Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registryJournal of Thrombosis and Haemostasis, 2010
- Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to ActionJournal of Clinical Oncology, 2009
- 2008 french national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working groupCritical Reviews in Oncology/Hematology, 2009
- 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working groupAnnals Of Oncology, 2009
- Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous ThromboembolismCirculation, 2008
- Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE RegistryThrombosis and Haemostasis, 2008
- Predicting recurrences or major bleeding in cancer patients with venous thromboembolismThrombosis and Haemostasis, 2008
- American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With CancerJournal of Clinical Oncology, 2007
- Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day PeriodClinical and Applied Thrombosis/hemostasis, 2006
- Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registryJournal of Thrombosis and Haemostasis, 2006